Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: What more do we need to know?

Journal of the International AIDS Society

Volumn 19, Issue 1, 2016, Pages

  Vitoria, Marco ^a   Hill, Andrew M ^b   Ford, Nathan P ^a   Doherty, Meg ^a   Khoo, Saye H ^b   Pozniak, Anton L ^c  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral treatment; Integrase inhibitors; Non nucleosides; Nucleoside analogues; Pregnancy; Protease inhibitors; Tuberculosis; Universal access

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; COBICISTAT; DOLUTEGRAVIR; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; 9-(2-((BIS(PIVALOYLOXYMETHOXY)PHOSPHINOYL)METHOXY)PROPYL)ADENINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; PHOSPHOROUS ACID;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; DRUG FORMULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCALE UP; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; HIV INFECTIONS; PUBLIC HEALTH;

ADENINE; ANTI-HIV AGENTS; BENZOXAZINES; DRUG THERAPY, COMBINATION; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; PHOSPHOROUS ACIDS; PUBLIC HEALTH; RITONAVIR;

EID: 84960192663     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.1.20504     Document Type: Review

References (61)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for the treatment and prevention of HIV Infection. Recommendations for a public health approach. 2013 [cited 2015 Mar 30]. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf
2. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
3. The TEMPRANO ANRS 12136 Study Group. Atrial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808-22.
4. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015 [cited 2015 Oct 27]. Available from: http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/
5. UNAIDS 2015. UNAIDS announces that the goal of 15 million people on life-saving HIV treatment by 2015 has been met nine months ahead of schedule. [cited 2015 Oct 27]. Available from: http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/july/20150714-PR-MDG6-report
6. UNAIDS. Fast-track - ending the AIDS epidemic by 2030. [cited 2015 Mar 30]. Available from: http://www.unaids.org/en/resources/documents/2014/JC2686-WAD2014report
7. Carey D. Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study. HIV Drug Therapy Glasgow Congress, 2-6 November 2014. Oral abstract 0421. J Int AIDS Soc. 2014;17(Suppl 3):19523.
8. Walmsley S, Berenguer J, Khuong-Josses M, Kilby JM, Lutz T, Podzamczer D, et al. Dolutegravir regimen statistically superior to efavirenz/tenofovir/emtricitabine: 96-week results from the SINGLE study (ING114467). Poster presented at: 21st Conference on Retroviruses and Opportunistic Infections; 2014 Mar 3-6; Boston, MA. Poster 543.
9. Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, et al. A randomized, double-blind comparison of tenofovir alafenamide vs tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat and emtricitabine, for initial HIV-1 treatment: week 96 results. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstract LBBPD1/1).
10. Gallant J, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arastah K, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emticitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;20:32-9.
11. Raffi F, Babiker A, Richert L, Molina JM, George E, Antinori A. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral naïve adults infected with HIV-1: 96 week results from the NEAT 001/ANRS143 randomised non-inferiority trial. Lancet. 2014;384:1942-51.
12. Rolon M. on behalf of the GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 96 week results of the GARDEL study. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstract PS10/4).
13. Clinton Health Access Initiative. HIV market report 2014. [cited 2015 Mar 30]. Available from: http://www.clintonhealthaccess.org/news-and-information/ARV-Market-Report-Dec2014
14. Barnhart M, Shelton J. ARVs: the next generation. Going boldly together to new frontiers of HIV treatment. Global Health Sci Pract. 2015;1:1-11.
15. Ford N, Shubber Z, Hill A, Vitoria M, Doherty M, Mills EJ, et al. Comparative efficacy of lamivudine and emtricitabine: a systematic review and metaanalysis of randomized trials. PLoS One. 2013;8(11):e79981. doi: http://dx.doi.org/10.1371/journal.pone.0079981
16. Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, et al. Pharmacokinetic and pharmacodynamics comparison of once-daily efavirenz (400 mg vs 600 mg) in treatment naïve HIV-infected patients: results of the ENCORE-1 study. Clin Pharmacol Ther. 2015;98:406-16.
17. Haas D, Hicks C, Seekins D, Cooper R, Gallant J, Carpenter C, et al. A phase II, double blind, placebo controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (DMP-266) in combination with open-label zidovudine with lamivudine at 24 weeks (DMP 266-005). 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb; Chicago, IL (abstract 698).
18. Hill A, Khoo S, Back D, Pozniak A, Boffito M. The drug interaction between rifampicin and efavirenz is time-dependent: systematic review of 12 pharmacokinetic studies. World AIDS Conference; 2014 July; Melbourne, Australia (abstract MOPE040).
19. Havlir D, Kendall M, Ive P, Kumwenda J, Swindells S, Qasba S, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482-3.
20. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, et al. Efficacy and safety of once-daily nevirapine-or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53:716.
21. Edurant prescribing information. [cited 2015 Oct 29]. Available from: http://www.drugs.com/pro/edurant.html
22. Hill A, Ford N, Boffito M, Pozniak A, Cressey T. Does pregnancy affect the pharmacokinetics of efavirenz? AIDS. 2014;28(10):1542-3.
23. Dooley K, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, et al. Phamacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection. J Infect Dis. 2015;211:197-205.
24. Olagunju A, Bolaji O, Amara A, Else L, Okafor O, Adejuyigbe E, et al. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin Pharmacol Ther. 2015;97(3):298-306.
25. National Institutes of Health. SSAT063 - Pharmacokinetics of efavirenz 400 mg once daily during pregnancy in HIV-1 infected women. [cited 2015 Nov 2]. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT02499874
26. MSF Drug Access Team. Untangling the web of antiretroviral price reductions. 17th ed. Geneva. 2014. [cited 2014 Dec 10]. Available from: http://www.msfaccess.org/content/untangling-web-antiretroviral-price-reductions-17th-edition-%E2%80%93-july-2014
27. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21-7.
28. Song I, Borland J, Arya N, Wynne B, Piscitelli S, et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015;55(5):490-6. doi: http://dx.doi.org/10.1002/jcph.439
29. European Medicines Agency (EMA). Dolutegravir summary of product characteristics. [cited 2015 Oct 29]. Available from: http://www.medicines.org.uk/emc/medicine/29178
30. National Institutes of Health. Open-label study of dolutegravir or efavirenz for human immunodeficiency virus (HIV) tuberculosis (TB) co-infection. [cited 2015 Mar 27]. Available from: http://clinicaltrials.gov/show/NCT02178592
31. National Institutes of Health. Safety and pharmacokinetics of dolutegravir in pregnant HIV mothers and their neonates: a pilot study (DolPHIN1). [cited 2015 Nov 2]. Available from: http://clinicaltrials.gov/ct2/show/NCT02245022
32. Mills A, Ortiz R, Crofoot G, McDonald C, Shalit P, Flamm J, et al. 48 Week study of the first PI-based single tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide s. darunavir (DRV) boosted by cobicistat (COBI) and emtricitabine/tenofovir disoproxil fumarate (TDF) in HIV-infected treatment naïve adults. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2014 Sep; Washington, DC (abstract).
33. Zack J, Doyle E, Graham H, Vimal M, West S, Quirck E. Bioequivalence of a fixed dose combination of rilpivirine/emtricitabine/tenofovir alafenamide to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and rilpivirine. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstract PE10/6).
34. Zack J, Doyle E, Cao H, Nichols A, West S, Quirck E. The effect of food on the rilpivirine/emtricitabine/tenofovir alafenamide single tablet regimen. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstr PE10/9).
35. Gilead Sciences. Tenofovir prescribing information. [cited 2014 Jan 7]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/021356s042,022577s002lbl.pdf
36. Custodio J, Garner W, Jin F, Cao H, Hepner M, Kearney B, et al. Evaluation of the drug interaction potential between the pharmacokinetic enhancer cobicistat and tenofovir disoproxil fumarate in healthy subjects. 14th International Workshop on Clinical Pharmacology of HIV Therapy; 2013 Apr 22-24; Amsterdam (abstract O-07).
37. Kearney B, Mathias A, Mittian A, Sayre J, Ebrahimi R, Cheng A. Pharmacokinetics and safety of tenofovir disoproxil fumarate on co-administration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278-3.
38. Hoetelmans R, Marien K, De Pauw M, Hill A, Peeters M, Sekar V, et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate. Br J Clin Pharm. 2007;65:655-61.
39. Atazanavir (Reyataz) prescribing information. [cited 2014 Jan 7]. Available from: http://packageinserts.bms.com/pi/pi-reyataz.pdf
40. Cooper R, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
41. Scherzer R, Estrella M, Li Y, Deeks S, Grunfeld C, Shlipak M. Association of tenofovir exposure with kidney disease. AIDS. 2012;26(7):867-75.
42. Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, et al. Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr. 2013;62: 375-80.
43. Ryom L, Mocroft A, Kirk O, Worm S, Kamara D, Reiss P, et al. Exposure to antiretrovirals (ARVs) and the risk of renal impairment among HIV-positive persons with normal baseline renal function: the DAD study. J Infect Dis. 2013;207(9):1359-69.
44. Sax P, Zolopa A, Brar I, Elion R, Ortiz R, Post F, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomised Phase 2 study. J Aqcuir Immune Defic Syndr. 2014; 67:52-8.
45. Agarwal K, Fung S, Nguyen T, Cheng W, Sicard E, Ryder S, et al. Twenty-eight day safety and efficacy of tenofovir alafenamide (TAF) fumarate in chronic hepatitis B (CHB) patients. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013); 2013 Nov 1-5; Washington, DC (abstract 973).
46. Mathias A, German P, Murray B, Wei L, Jain A, West S, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010;87:322-9.
47. UNITAID/WHO. HIV medicines: technology and market landscape. 1st ed. [cited 2015 Mar 30]. Available from: http://www.unitaid.eu/en/about/market-approach/9-uncategorised/345-technical-reports#hiv
48. Ramanathan S, Waren D, Wei L, Kearney B. Pharmacokinetic boosting of ataznavir with the pharmacoenhancer GS-9350 versus ritonavir. 49th ICAAC; 2009 Sep; San Francisco, CA (abstract A1-1301).
49. Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu H, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS. 2011;25:1881-6.
50. Kakuda T, Opsomer M, Timmers M, Iterbeke K, De Casteele T, Hillewart V, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014;54:949-57.
51. Tashima K, Crofoot G, Tomaka F, Kakuda T, Brochot A, Van de Casteele T, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11:39.
52. Battegay M, Elzi L. Does antiretroviral therapy still need its backbone? Lancet. 2014;384:1908-10.
53. Girard PM, Pozniak A, Hill A, Hadacek B, Moecklinghoff C. Does two-drug therapy show equivalent efficacy to standard three-drug combinations? Metaanalysis of 14 randomised trials in 3323 patients. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstract PE7/3).
54. Paton N, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014;371:234-47.
55. Amin J, Boyd MA, Kumarasamy N, Moore CL, Losso MH, Nwizu CA, et al. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS One. 2015;10(2):e0118228.
56. Di Giambenedetto S, Fabbiani M, Quiros-Roldan E, Latini A, D'Ettore G, Antinoi A, et al. Simplification to atazanavir/ritonavir + lamivudine versus maintaining atazanavir/ritonavir +2NRTIs in virologically suppressed HIV-infected patients: 48-weeks data of the ATLAS-M trial. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstract BPD1/6).
57. Arribas J, Girard PM, Landman R, Pich J, Mallolas J, Martinez-Rebollar M, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;7:785-92.
58. Perez-Molina J, Rubio R, Rivero A, Pasquau J, Suárez I, Riera M, et al. Dual treatment with atazanavir/ritonavir + 3TC vs. triple treatment with atazanavir/ritonavir + 2 nucleosides) in virologically stable patients with HIV-1 (SALT study): 96-week results from a randomized, open-label, non-inferiority trial. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstract PE 7/6).
59. Pinola M, Lazzarin A, Antinori A, Carosi G, Di Perri G, Moroni M, et al. Lopinavir/ritonavir + tenofovir dual therapy versus lopinavir/ritonavir-based triple therapy in HIV-infected antiretroviral naïve subjects: the Kalead study. J Antivir Antiretrovir. 2010;2:56-62.
60. Figueroa M, Sued O, Patterson P, Gun A, Rolon M, Cahn P. Dolutegravir-lamivudine as dual therapy in naive HIV-infected patients: first results of the PADDLE trial. 15th European AIDS Conference; 2015 Oct; Barcelona, Spain (abstract LBPS4/2).
61. Hill A, Sabin C. Designing and interpreting HIV noninferiority trials in naïve and experienced patients. AIDS. 2008;22:913-21.